David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

The Time to Buy MULN Stock Is Now

By David Moadel, InvestorPlace Contributor

MULN stock will undoubtedly be volatile and could go lower for a while. However, patient Mullen shareholders will have the last laugh.

Is DOCU Stock a Buy? The Answer Is Definitely Yes!

By David Moadel, InvestorPlace Contributor

DOCU stock investors might finally have some breathing room this year as DocuSign charts a comeback course with a new chief executive.

Why Is Sidus Space (SIDU) Stock Up 20% Today?

By David Moadel, InvestorPlace Contributor

SIDU stock is rocketing higher as Sidus Space discloses an agreement to help build essential equipment for the U.S. military.

PFE Stock Alert: What to Know as Pfizer Prepares to Manufacture Paxlovid in China

By David Moadel, InvestorPlace Contributor

A Covid-19 surge in China is offering Pfizer an opportunity to generate revenue, but PFE stock is stuck in neutral for now.

Why You Should Invest $100 in BALY Stock Now

By David Moadel, InvestorPlace Contributor

BALY stock shouldn't be anyone's main portfolio holding. However, it could provide surprising returns as Bally works to reduce its debt.

Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal

By David Moadel, InvestorPlace Contributor

Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.

Genesis Layoffs 2023: What to Know About the Latest Crypto Lender Job Cuts

By David Moadel, InvestorPlace Contributor

Bitcoin holders seem to be taking the news in stride today, but Genesis layoffs are a cause for concern as the FTX domino effect persists.

DCP Stock Pops on Phillips 66 Acquisition News

By David Moadel, InvestorPlace Contributor

DCP stock holders are in a good mood today as DCP Midstream reaches a highly favorable agreement with an American oil-and-gas giant.

SOFI Stock: The Case for SOFI Hitting $10 in 2023

By David Moadel, InvestorPlace Contributor

One prominent analyst is calling the downside risk for SOFI stock "extremely minimal," so there's no need to panic-sell now.

NovoCure (NVCR) Stock Soars 50% on Positive Clinical Trial Results

By David Moadel, InvestorPlace Contributor

NVCR stock traders are undeniably pleased to see NovoCure marking a milestone in the company's quest to treat a specific type of lung cancer.

Load More